Maryland is currently home to 2681 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
NCT06453213
Recruiting
Cenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of Partial-Onset (focal) seizures in adult subjects (≥18 years of age). In the US it is approved for use as monotherapy, however, there is little clinical data assessing its use as monotherapy in adults with POS. This study is designed to explore the effectiveness of doses of 100 mg/day and 200 mg/day as monotherapy in adult subjects with newly diagno... Read More
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
03/25/2025
Locations: John Hopkins Epilepsy Center, Baltimore, Maryland
Conditions: Focal Onset Seizure
Register for Updates
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
NCT06401421
Recruiting
The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Greater Baltimore Medical Center, Baltimore, Maryland
Conditions: Breast Cancer
Register for Updates
Nightmare Deconstruction and Reprocessing vs. NightWare Wristband
NCT06399874
Recruiting
The overall goal of this Phase IIa randomized controlled pilot trial is to assess the potential efficacy of two emerging treatments for post-trauma nightmares and to test the feasibility of study design and methods. Symptom change will be assessed in two treatment arms: (1) Nightmare Deconstruction and Reprocessing (NDR), an exposure-based psychotherapy; and (2) NightWare (NW), a non-exposure approach using a wristband device. The investigators will also assess the feasibility of circadian-depen... Read More
Gender:
ALL
Ages:
Between 22 years and 64 years
Trial Updated:
03/25/2025
Locations: Uniformed Services University of the Health Sciences, Bethesda, Maryland
Conditions: Nightmare
Register for Updates
A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
NCT06362265
Recruiting
The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
03/25/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Type 2 Diabetes Mellitus
Register for Updates
Study of Plozasiran in Adults With Severe Hypertriglyceridemia
NCT06347016
Recruiting
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After Month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Annapolis Internal Medicine, Annapolis, Maryland
Conditions: Severe Hypertriglyceridemia
Register for Updates
NIDCD Otolaryngology Clinical Protocol Biospecimen Bank
NCT06303180
Recruiting
Background: Many disorders of the head and neck can affect a person s hearing; balance; smell; taste; swallowing; voice; or speech. These disorders include cancers and genetic and inflammatory diseases. To find better ways to diagnose and treat these disorders, researchers need to study tissues and other biological samples from people who have them. Objective: To collect biological samples for a repository that will be used for research. Eligibility: People of any age with a disorder of the... Read More
Gender:
ALL
Ages:
Between 3 years and 99 years
Trial Updated:
03/25/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Hearing Loss, Head and Neck Neoplasms, Hearing Disorders, Laryngeal Disease
Register for Updates
Parasitic Ulcer Treatment Trial
NCT06213649
Recruiting
The Parasitic Ulcer Treatment Trial (PUTT) is a multi-center, parallel-group, randomized clinical trial. The purpose of this study is to determine whether including topical corticosteroids in a regimen for acanthamoeba keratitis (AK) will improve vision. Patients presenting to all enrollment centers with evidence of acanthamoeba keratitis will be eligible for the trial if there is evidence of ocular inflammation after 4 weeks of anti-amoebic therapy. Those who agree to participate will be random... Read More
Gender:
ALL
Ages:
8 years and above
Trial Updated:
03/25/2025
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Acanthamoeba Keratitis
Register for Updates
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
NCT06143891
Recruiting
This is a parallel, Phase 3, two-arm study for the treatment of newly diagnosed moderate or severe chronic GVHD. The study duration for a participant includes up to 4 weeks for screening; a treatment period until clinically meaningful cGVHD progression (defined as progression requiring addition of new systemic treatment for cGVHD), relapse/recurrence of the underlying disease, participant starts new systemic treatment for cGVHD or experiences an unacceptable toxicity, at the request of the part... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/25/2025
Locations: Johns Hopkins Hospital- Site Number : 8400033, Baltimore, Maryland
Conditions: Chronic Graft Versus Host Disease
Register for Updates
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
NCT06096870
Recruiting
Background: Prostate cancer may return after treatment in 30,000 to 50,000 people each year. There is no clear best way to treat these people. Better treatments are needed. Objective: To test a study drug (enzalutamide), both alone and combined with a second drug (PDS01ADC), in people with prostate cancer that returned after treatment. Eligibility: People aged 18 years and older with prostate cancer that returned after treatment. Design: Participants will be screened. They will have a phy... Read More
Gender:
MALE
Ages:
Between 18 years and 120 years
Trial Updated:
03/25/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Prostate Cancer, Recurrent Prostate Cancer, PET Positive
Register for Updates
Cardamom and Topical Roseomonas in Atopic Dermatitis
NCT06096857
Recruiting
Background: Atopic dermatitis (AD), also called eczema, is a chronic skin condition. AD can make skin dry and itchy, and sometimes it can lead to serious health problems, such as asthma, food allergies, eye infections, and sleep problems. No cure exists for AD. Researchers know that people with AD have different kinds of harmless bacteria on their skin than do people without AD. They want to see if adding a harmless bacteria (Roseomonas mucosa) to the skin can help people with AD. Objective:... Read More
Gender:
ALL
Ages:
Between 2 years and 100 years
Trial Updated:
03/25/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Atopic Dermatitis, Eczema
Register for Updates
Study to Assess the Safety and Effectiveness of NMRA-335140-501
NCT06029439
Recruiting
This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), who provide informed consent, and who have no evidence of safety concerns that would preclude treatment with NMRA-335140 may be enrolled into this ext... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/25/2025
Locations: Neumora Investigator Site, Baltimore, Maryland
Conditions: Major Depressive Disorder
Register for Updates
A 2-stage, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
NCT06015737
Recruiting
This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with cutaneous lupus erythematosus (CLE).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/25/2025
Locations: Research Site, Baltimore, Maryland
Conditions: Cutaneous Lupus Erythematosus
Register for Updates